USRM has ~X2 revs & ~X3 profits, ~X4 Assets, ~X3.5 Cash in 1 year (from Sept 2016-2017) set up for move to new highs, and brought in $1.5 million in revs & $1 million of gross profit last Q alone

There is so much more going for the company now versus earlier this year when it was trading with a VWAP between $.075-$.14 for 80+ trading days and especially last year or what ever happened almost ten years ago. I am looking forward to more and more revenue growth with overseas expansion with Kuwait and hopefully more trials and updates on RMAT. One big spark and the game changes.

A $15.5 million market cap @ $.0469 could easily be $100mil market cap which would be ~$.30/share. I have seen much much much worse see much higher. A valuation correction is well over due if you ask me and it seems others are beginning to agree. The company knows what it needs to do. They have said time adn time again . They doubled revs and tripled profits in 1 year and the stem cell market is growing at an insane rate. Thanks for the cheap shares, especially the last 3 months.


Key growing financials
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017

Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)

Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017

2016 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11674975
2017 Q1 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12033381
2017 Q2 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12218852
2017 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12365541

I think this is a dollar stock. Looking forward for the next few weeks :).

If anyone can share the presentation from today that would be great

Close at .09 its looking like...great show, tempted to jump in

I see Tencent bring surprises to the table no one saw coming

Gonna be a 45 degree kind of day ;)

Those fake etrf walls show people dont want it out just yet. It'll flirt a lil but then correct itself life it should above $.10+

It traded above .~07 for about 11 weeks (about 3 months)

Looking forward to see what Tencent brings to the table

Oh and looks like another golden cross on the way before years end :) last golden cross was in mid March. The 2 years daily chart is something of beauty if you ask me. I am getting ready

I would buy that in a heartbeat :) $USRM on track for new levels

Cheers Cheers Cheers

False claims. Please use this board as a discussion point about the stock. Excited to see news spreading!!!

Breakoutboard coming this week, its insane the progress YoY and QoQ that USRM is putting together. Cheers

:) :) :) those candles look beautiful. Excited for Kuwait and RMAT updates

Very very excited for the next 2 months

They were already blind. Old news. Future and present are looking amazing. Thankful for $USRM buddddddddy

Stars are aligning :)

"USRM intends to take full advantage of this RMAT opportunity and join strategic partners to apply for consideration of its MyoCell product for heart failure patients."

http://us-stemcell.com/u-s-stem-cell-responds-to-fdas-regenerative-medicine-guidelines/

Excited times ahead

$USRM continues to grow I expect an announcement from company soon enough on framework and Kuwait. Thanks for your interest and opinion though! This is my opinion. Thats whats great about the stock market haha everyone has their own opinion but no one can stop the future of medicine

Per Bloomberg

"Financial Statements For Us Stem Cell Inc (USRM)
Compared to the same quarter last year, U.S. Stem Cell, Inc. has been able to grow revenues from $729.8K USD to $1.5M USD. Most impressively, the company has been able to reduce the percentage of sales devoted to selling, general and administrative costs from 193.74% to 134.35%. This was a driver that led to an improvement in the bottom line from a loss of $1.7M USD to a smaller loss of $931.7K USD."

http://www.investing.businessweek.wallst.com/research/stocks/financials/financials.asp?ticker=USRM&dataset=incomeStatement&period=Q¤cy=native

Nice slapping is right. YOU COULDNT BE MORE RIGHT ABOUT HOW amazing the conpany is. Looking forward to response to public

I dont come around for nothing :)

Itll be eaten up by days end

FYI, When they do non-homologous use of tissue it is conducted my a medical practitioner, and per the exception clause under section 351 vs 361 PHS Act they are not required to comply with the requirements of this part.

What they are doing now is legal and looks like USRM fits the criteria of these guidelines for their therapies.

CHEERS BUDDY!

Wrong wrong wrong, this was the best thing that couldve happened for them. Cheers all!!!

FDA announces comprehensive regenerative medicine policy framework to spur innovation, efficient access to potentially transformative products, while ensuring safety and efficacy https://go.usa.gov/xnZ4M

"New Final Guidance Documents

The two final guidance documents clarify the FDA’s interpretation of the risk-based criteria manufacturers use to determine whether a product is subject to the FDA’s premarket review.
The first guidance provides greater clarity around when cell and tissue-based products would be excepted from the established regulations if they are removed from and implanted into the same individual within the same surgical procedure and remain in their original form. The second final guidance helps stakeholders better understand how existing regulatory criteria apply to their products by clarifying how the agency interprets the existing regulatory definitions “minimal manipulation” and “homologous use.” As this field advances, the FDA has noted that there are a growing number of regenerative medicine products subject to FDA premarket authorization. These guidance documents will help explain how the FDA will provide a risk-based framework for its oversight. The policy framework defines how we intend to take action against unsafe products while facilitating continued innovation of promising technologies.

To accomplish this goal, the guidance document has clarified the FDA’s view of “minimal manipulation” and “homologous use.” These are two concepts that are defined in current regulation to establish the legal threshold for when a product is subject to the FDA’s premarket approval requirements. By further clarifying these terms in the final guidance, the FDA is applying a modern framework for its oversight. Under the new policy, in order to allow manufacturers of products time to comply with the requirements, for the first 36 months following issuance of the final guidance document the FDA intends to exercise enforcement discretion for certain products that are subject to the FDA’s premarket review under the existing regulations, but are not currently meeting these requirements. The FDA does not intend to exercise such enforcement discretion for those products that pose a potential significant safety concern. Going forward, the FDA will apply a risk-based approach to enforcement, taking into account how products are being administered as well as the diseases and conditions for which they are being used. This risk-based approach allows product manufacturers time to engage with the FDA, as to determine if they need to submit a marketing authorization application and, if so, submit their application to the FDA for approval."


Cheers!

Sorry you feel that way. Guidelines are huge and once clarified USRM will jump back in :)

$USRM cant wait to see where this heads. I expect some surprises before year end, lots of good stuff going on, Excited to see Kuwait clinic and the recent announcement of the FDA 2 day Regenerative/stemcell event in San Fran + soon to be RMAT guidelines by mid December. Lots of exposure and the media will

OS unchanged since last TA update Nov 1st on OTC markets. Nov 13th shows same as the #

"RIGHT NOW" in all caps was the biggest give away in the article.

Cheers to the future of medicine :)

More like 37s bud. Haha nice try

Strong green Friday close it is looking like, exciting times ahead :)

Lots too happen before the end of the year. Kuwait and FDA guidelines.

Also, looks like news got around about whats going on here.( Recent publications and revs :).)

Those slaps today were wonderful. Looking forward to more tomorrow. Imagine when tens of millions of shares trade hands.... $USRM

An investors lack of knowledge doesnt mean lack of activity for the stock. Obviously they are expanding QoQ and working towards making their shares worth something.

I ignire the noise and do just fine. Cheers

Thank you thank you, exciting times ahead.

$USRM UPDATE as of November 8th, 2017 per 10Q & recent studies

Link to Journal of Clinical Medicine published November 2017 with Kristin's study. http://www.jocmr.org/index.php/JOCMR/article/view/3187

"The study, called "Safety Analysis of Autologous Stem Cell Therapy in a Variety of Degenerative Diseases and Injuries Using the Stromal Vascular Fraction," is the largest safety trial to date that used stem cells from fat. It was published in the Journal of Clinical Medicine Research and co-authored by U.S. Stem Cell, Inc. Chief Science Officer Kristin Comella, PhD, as well as Michelle Parlo, PA, Rosemary Daly, DO, Vincent Depasquale, DC, Eric Edgerton, DC, Patrick Mallory, DO, Roy Schmidt, MD, Walter P. Drake, PhD.
"
from study-
"Competing Interests
KC is an officer of US Stem Cell, Inc.
Funding
This study was partially funded by US Stem Cell, Inc."

Key growing financials
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017

Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)

Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017


Share Structure
341,284,823 shares issues and outstanding as of Nov 2017
337,417,859 shares issued and outstanding as of Sept 2017
336,461,515 shares issued and outstanding as of June 2017


Kuwait Clinic
"The US Stem Cell Clinic in Kuwait is currently under construction and is expected to open before the end of the year" Page 31 of recent 10 Q
There are Job postings/ Job descriptions on USRM's websites, for the Kuwait clinic. I am guessing this means they will have some ownership with the Kuwait clinic thus another big source of revenue.

Customers
"As of September 30, 2017, four customers, one of which is a related party ( US Stem Cell Clinic LLC, a partly owned investment in which the Company holds a 33% member interest), represented 25%, 15%, 16%, and 21% of accounts receivable, respectively, representing an aggregate of 77% of the Company’s accounts receivable. As of December 31, 2016, four customers, one of which is the same related party above, represented 45%, 13%, 13%, and 12% of accounts receivable respectively, representing, an aggregate of 83%, of the Company’s accounts receivable."

4 Customers responsible for so much business is very normal, 80/20 applies to most businesses and for USRM is seems that the 4 customer's percentage is shrinking, overall, showing growth with other customers while revenues increasing. Very good sign. (Those four customers don't mean four clinics)

Compliance

US Stem Cell Clinic, LLC, (“SCC”), a partially owned investment of our company (in which we have a 33% member interest), is a physician run regenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.

Market Growth

"According to the Scalar Market Research Stem Cell Therapy Analysis Global Revenue, Trends, Growth, Share, Size and Forecast to 2022, the stem cell therapy market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022." per page 30 of recent 10Q


Link to articles
http://www.baystreet.ca/viewarticle.aspx?id=480636
http://us-stemcell.com/us-stem-cell-reports-3q/

Will reply to this with more info, had to throw this together quickly, works been crazy

The growth YoY and QoQ is insane. Cheers to all. Will write another updated analysis like the sticky later tonight

Pretty clear. No need for me to repeat myself. All the info is out there. It really is cool how much this company is doing to help people in pain while building an impressive business model

Very impressive

Look at FDA deliverable for the 21st century cures act on their websitr. They are ahead of schedule on some items and the deadlines I saw pertaining to regenerative medicine info is around mid Dec. I think Dec12th/13th. Ill check once I get home. Cant wait to see news get around about this

Almost 300 clinics use their tech while revs and bottom continue to grow QoQ. +Recent safety trial with almost 700 people and news clinics using their tech continue to grow while the regenerative med market CAGR% is close to 20% YoY. Good luck ALL :)